The Oxford Academic Health Science Network gets innovation into clinical practice to improve patient safety, outcomes and experience, and generate economic growth through collaboration between the NHS, industry and universities. We cover a region of three million people living in Berkshire, Buckinghamshire, Milton Keynes and Oxfordshire. We aim to foster long term partnerships with industry, build a culture of innovation in the NHS, and have secured over £100 million of investment into the Thames Valley region. Our specialist capabilities include diagnostics and precision medicine, early innovator support and market access. You can find out more about how we can help on our website.
Find your nearest AHSN
The Oxford AHSN region has identified five local challenges; Increasing out-of-hospital care, redesigning and reducing pressure on hospital emergency services, offering more personalised care, digitally-enabled primary and outpatient care, improving outcomes by population health initiatives.
The Oxford Academic Health Science Network has extensive experience in real world evaluation projects, with the aim of gathering enough evidence to create a business case for these innovations.
MetaGuideX is a diagnostic research company that has developed an accurate, fast, non-invasive diagnostic for predicting metastasis (spread of cancer cells) with high specificity and sensitivity. With this tool, they aim to redefine the cancer care pathway. The tool is designed to be used alongside existing standard investigation methods to reduce the need for lymph node biopsies, saving the patient from unneeded procedures and the NHS money.
Cobas® Liat® influenza test
The cobas® Liat® System is a fast, easy-to-use, compact PCR system designed for on-demand testing in point-of-care settings such as clinics, pharmacies, and hospital and satellite laboratories. The Oxford AHSN assisted in the first UK based evaluation of the the cobas® Liat® Influenza A/B test, in the Emergency Department (ED) of the Royal Berkshire Hospital, which provides secondary emergency care for most of Berkshire. The test is a PCR based test using either nasopharyngeal or throat swabs and requires minimal sample preparation. The evaluation aimed to see if the test reduced patient length of stay, reduced antibiotic use and increased the use of antivirals.
Eight ventures pitch for investment
On 27 November, eight innovative start-ups from the Oxford AHSN Accelerator, delivered by BioCity pr...